COMPANY NEWS
Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List
2019.08.21 Download
Hong Kong, 21 August 2019

Essex Bio-Technology Limited (“EssexBio” or the “Group”, Stock code: 1061) today is pleased to announce that Recombinant Bovine Basic Fibroblast Growth Factor (rb-bFGF) Gel (Product series: Beifuxin) has been newly admitted to the latest National Drug List for Basic Medical Insurance, Work Related Injury Insurance and Maternity Insurance (“NDL”) issued by National Healthcare Security Administration and the Ministry of Human Resources and Social Security of the People’s Republic of China on 20 August 2019, whilst the other three bio-pharmaceutical products that were previously included in 2017 NDL remain to be listed.

Details of the Group’s listed bio-pharmaceutical products are set out below:
Product series Product form Common name Status
Beifushu Eye Drops recombinant bovine basic fibroblast
growth factor (rb-bFGF)
Class B (No. 444)
Beifushu Eye Gel recombinant bovine basic fibroblast
growth factor (rb-bFGF)
Class B (No. 444)
Beifuji Lyophilized Powder recombinant bovine basic fibroblast
growth factor (rb-bFGF)
Class B (No. 447)
Beifuxin Gel recombinant bovine basic fibroblast
growth factor (rb-bFGF)
Class B (No. 447)

The Board of Directors believe that the inclusion of Beifuxin, the largest turnover contributor of the Company, into NDL will further accelerate the expansion of distribution network of the Group’s flagship bio-pharmaceutical products in PRC and provide a strong impetus for organic growth in the immediate future.
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
市区开早餐店赚钱吗 广西快乐双彩好运开奖 吉林11选五开奖号和遗漏号 贵州快三开奖走势一定牛 宁夏体彩经网彩十一选五走势图 每日短线股票推荐 怎样下载吉林十一选五 无门槛提现赚钱APP 泳坛夺金481口诀 黑龙江22选5开奖结果8月8 期货配资流程步骤